Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice
- سال انتشار: 1402
- محل انتشار: بیست و چهارمین کنگره بین المللی میکروب شناسی ایران
- کد COI اختصاصی: MEDISM24_068
- زبان مقاله: انگلیسی
- تعداد مشاهده: 133
نویسندگان
Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Department of Medical Bacteriology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Department of Medical Bacteriology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Immunobiochemistry laboratory, Immunology Research Center, Bu-Ali Research Institute, Mashhad, Iran
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad Iran
چکیده
BACKGROUND AND OBJECTIVESTuberculosis (TB), a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), remains a health problem worldwide and this infection has the highest mortality rate among bacterial infections. Current studies suggest that intranasal administration of new tuberculosis vaccines could enhance the immunogenicity of M. tuberculosis antigens. Hence, we aim to evaluate the protective efficacy and immunogenicity of HspX/EsxS fusion protein of M. tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA through the intranasal administration in mice model.MATERIALS AND METHODSIn present study, the recombinant fusion protein was expressed in Escherichia coli and purified and used to prepare different nanoparticle formulations in combination with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA. Mice were intranasally vaccinated with each formulation three times at an interval of ۲ weeks. Three weeks after final vaccination, IFN-γ, IL-۴. IL-۱۷ and TGF-β concentration in supernatant of cultured splenocytes of vaccinated mice as well as serum titers of IgG۱ and IgG۲a and sIgA titers in nasal lavagewere determined.RESULTS AND DISCUSSIONAccording to obtained results, intranasally vaccinated mice with formulations containing ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA could effectively induced IFN-γ and sIgA responses. Moreover, both HspX/EsxS/ISCOMATRIX/MPLA and HspX/EsxS/PLUSCOM/MPLA and their BCG booster formulation could strongly stimulate the immune system and enhance the immunogenicity of M. tuberculosis antigens.CONCLUSIONThe results demonstrate the potential of HspX/EsxS-fused protein in combination with ISCOMATRIX, PLUSCOM and MPLA after nasal administration in enhancing immune response against of M. tuberculosis antigens. Both nanoparticles were good adjuvants in order to promote immunogenicity of TB fused antigen. So, nasal immunization with these formulations, could induce immune responses and considered as new TB vaccine or as BCG booster.کلیدواژه ها
Mycobacterium tuberculosis, HspX/EsxS, ISCOMATRIX, PLUSCOM, MPLA, Nasal administration.مقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.